Corxel raises $287M to advance oral GLP-1 candidate CX11

Corxel Pharmaceuticals has closed a major growth round, securing $287 million in a Series D1 financing to accelerate development of its cardiometabolic pipeline, led by its oral small‑molecule GLP‑1 receptor agonist CX11.

The round drew a syndicate of healthcare investors, including RTW Investments, SR One, TCG Crossover (TCGX), RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital and existing backer Hengdian Group Capital. The group will support expansion of CORXEL’s clinical programmes and global operations.

Corxel said proceeds will primarily fund advancement of CX11 — an oral GLP‑1 receptor agonist being evaluated for obesity and overweight patients in a U.S. Phase 2 study and in a Phase 3 programme conducted by Vincentage in China — and to prepare additional global Phase 2 and Phase 3 activities, including planned trials in Type 2 diabetes (T2DM). The company also intends to push forward other cardiometabolic programs, notably assets targeting acute ischemic stroke and hypertension.

Chief Executive Officer Sandy Mou described the financing as a watershed moment for CORXEL, saying the capital will “propel the company to a new orbit of growth” by enabling multiregional development and bolstering clinical operations. Investors cited confidence in CORXEL’s clinical execution and the differentiated profile of CX11.

Strategic governance moves accompany the fundraising: CORXEL said that SR One, TCGX and other participants will nominate three new representatives to the company’s board, reflecting hands‑on investor oversight as CORXEL scales global trials.

Market context underscores the timing. GLP‑1 receptor agonists have reshaped the cardiometabolic landscape: injectable GLP‑1s from large pharma have driven unprecedented demand for obesity and diabetes therapies and pushed the broader market into double‑digit growth. Oral small‑molecule approaches such as CX11 aim to capture patients seeking pill‑based alternatives to injectables; analysts have flagged the oral GLP‑1 opportunity as a strategic frontier in a market poised to expand materially over the coming decade.

For CORXEL, the new funds de‑risk near‑term clinical milestones while enabling parallel investment in non‑GLP cardiometabolic projects. The raise also strengthens the firm’s ability to run simultaneous multiregional trials — an increasingly important capability as regulators and payers focus on geographically diverse evidence for cardiometabolic indications.